Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2066 - Distribution of lymph node metastases can have an impact on survival benefit of oxaliplatin-containing chemotherapy in stage III colon cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Pathology/Molecular Biology

Tumour Site

Colon and Rectal Cancer

Presenters

Yeesoo Chae

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

Y. Chae1, J.G. Kim2, J.H. Baek3, S.J. Lee2, D.W. Baek2, B.W. Kang2

Author affiliations

  • 1 Oncology, Kyungpook National University Medical Center, 702-911 - Daegu/KR
  • 2 Oncology, Kyungpook National University Hospital, 700-721 - Daegu/KR
  • 3 Oncology, Ulsan University Hospital, 44033 - Ulsan/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2066

Background

This study investigated the effect of oxaliplatin-containing adjuvant chemotherapy according to the distribution of lymph node (LN) metastases for patients with stage III colon cancer (CC).

Methods

Among 1554 patients with CRC who underwent surgical resection between 2010 and 2014, 254 patients were diagnosed with stage III CC, and adjuvant chemotherapy was administered. Patients were treated with either oxaliplatin-containing chemotherapy or non-oxaliplatin-containing chemotherapy according to each investigator decision. LN distribution was classified on the basis of the Japanese classification of colorectal carcinoma. The patients were grouped into two categories: pericolic LN-positive and extrapericolic LN-positive.

Results

Among the 254 patients enrolled in this study, 175 belonged to the PLN group, whereas the remaining 79 patients to the ELN group. The PLN group was also divided into two groups based on the regimen: 79 patients were included in the non-oxaliplatin-containing chemotherapy group, while 96 in the oxaliplatin-containing chemotherapy group. The characteristics were similar between two groups, except for age and body mass index. During the median follow-up duration of 48.5 months (range 4.7-94.0), 39 (15.4%) patients died and 47 (30.5%) patients experienced recurrence and the estimated DFS and OS at 3 years was 82.8% and 90.1%, respectively. In the univariate analysis, oxaliplatin chemotherapy was not significantly associated with DFS (p = 0.457) and OS (p = 0.147). In the multivariate analysis, the addition of oxaliplatin showed no prognostic significance on DFS (p = 0.073) and OS (p = 0.594).

Conclusions

In conclusion, oxaliplatin-containing adjuvant chemotherapy was not found to have a significant effect on survival for stage III CC patients with only PLN. Accordingly, the current study can provide a novel strategy for subgroups with limited LNs distribution, considering that the state of the LN distribution is a critical factor for therapeutic success.

Clinical trial identification

Legal entity responsible for the study

Jong Gwang Kim.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.